Rights issue 2022

On October 3, 2022, Boule Diagnostics AB (publ) (“Boule” or the “Company”) announced that the Board of Directors resolved, subject to approval by an Extraordinary General Meeting, on an issue of shares of approximately SEK 150 million with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The Board of Directors’ resolution on the Rights Issue was approved by the Extraordinary General Meeting held on November 1, 2022. The purpose of the Rights Issue is to finance the completion of the new product platform, regulatory processes related to launches as well as commercialization of the new hematology platform, including a new advanced 5-part system, a new 3-part system and a cloud connectivity solution.

Shareholders in Boule have the preferential right to subscribe for one (1) new share per every one (1) existing share, i.e. a subscription ratio of 1:1. The subscription price is SEK 7.70 per share. The Rights Issue comprises a maximum of 19,416,552 shares. The Rights Issue is fully secured through subscription undertakings, guarantee undertakings and intentions to subscribe for shares. Assuming that the Rights Issue is fully subscribed, the Company will receive issue proceeds of approximately SEK 150 million before deduction of issuance costs. Investors are referred to the prospectus below for complete information regarding the Rights Issue.

Timetable for the Rights Issue
November 8, 2022 Last day of trading including the right to receive subscription rights
November 9, 2022 First day of trading without the right to receive subscription rights
November 10, 2022 Publication of the prospectus
November 10, 2022 Record date for participation in the Rights Issue with preferential rights
November 14 – November 28, 2022 Subscription period
November 15 – November 23, 2022 Trading in subscription rights
November 30, 2022 Announcement of the outcome of the Rights Issue

Press releases

Change in number of shares and votes in Boule Diagnostics

Boule Diagnostics resolves on a fully secured preferential rights issue of approximately SEK 150 million


Bulletin from the extraordinary general meeting in Boule Diagnostics on November 1, 2022

Boule Diagnostics publishes prospectus in connection with its Rights Issue – Boule

Trading of subscription rights commences Tuesday 15 November

Boule Diagnostics raises approximately SEK 150 million through a significantly oversubscribed rights issue

Related documents
Prospectus (Swedish)

Application form without preferential right  (Swedish)

Certificate of registration